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Discussions about the intersection of patent law and antitrust law generally 
focus on those areas in which tension apparently exists. Complications, however, 
also exist when the two bodies of law condemn the same conduct. For example, 
both patent law and antitrust law condemn patent fraud. Because each area of law 
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employs its own elements and remedies, the Federal Circuit has drawn some 
artificial distinctions. This Article illustrates this point using the Federal Circuit’s 
treatment of patent applicants’ omission of material sales information. 
Part I introduces the on-sale bar, which precludes a patent from issuing on 
an invention that has been sold or offered for sale more than one year before a 
patent application is filed. The Patent and Trademark Office (PTO) depends on 
patent applicants to disclose prior sales activity because it is difficult or impossible 
for patent examiners to discover such sales on their own. Unfortunately, some 
patent applicants decide to conceal their prior sales activity from the Patent 
Office, which leads to the issuance of patents that violate the on-sale bar.  
Part II examines the legal consequences of an applicant’s failure to disclose 
prior sales activity that is deemed material. First, the omission may constitute 
inequitable conduct, which renders the patent unenforceable. Second, the 
omission may constitute fraud, which could form the basis of an antitrust 
violation if the patentee has monopolized a relevant market. The former is a 
patent defense, the latter an antitrust cause of action that entitles the successful 
plaintiff to treble damages from the patentee. Because the consequences of finding 
fraud are greater than finding inequitable conduct, courts require a higher degree 
of scienter for fraud. This heightened standard for antitrust liability risks rendering 
fraud by omission cost-beneficial because concealing prior sales can be profit 
maximizing even if the patent applicant is eventually caught.  
Part III proposes that the standard for deceptive intent used in antitrust 
claims based on patent fraud should more closely mimic the test used for 
inequitable conduct purposes. This change reflects that the fact that the intent to 
deceive the PTO is the same regardless of whether the legal issue at hand is the 
inequitable conduct defense or an antitrust claim. Courts should not require more 
evidence to prove deceptive intent for Walker Process purposes than for inequitable 
conduct purposes. Employing a more unified deceptive intent standard should 
lead to more appropriate disclosure of relevant sales activity. The two legal 
doctrines would remain distinct, however, because the test for materiality is more 
rigorous for antitrust claims than for the inequitable conduct defense and because 
the antitrust cause of action requires plaintiffs to prove several additional 
elements.  
Finally, Part IV addresses the concerns that some may have about the 
changes proposed in Part III. These include: the fear that making it easier for 
patent challengers to show deceptive intent is equivalent to strict liability; the cost 
to patent applicants of having to produce more information; and the possibility of 
encouraging wasteful overcompliance by patent applicants. 
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I. INVALID PATENTS, THE ON-SALE BAR, AND THE PROBLEM OF OMISSIONS 
The Patent Office issues many patents that courts subsequently declare to be 
invalid. Close to half of litigated patents are pronounced invalid.1 The high 
number of invalid patents is a function of several factors. Patent examiners have 
little time to review each application—as little as “8 to 25 hours to read and 
understand each application, search for prior art, evaluate patentability, 
communicate with the applicant, work out necessary revisions, and reach and 
write up conclusions.”2 The patent examiner bears the burden of proving that a 
patent should not issue. Because the patent applicant has no duty to research for 
prior art, the time-strapped and resource-constrained patent examiner is likely to 
be unaware of patent-invalidating prior art in many cases. 
Invalid patents undermine both the patent system and the competitive 
marketplace. They raise entry costs and delay market entry, deter customers and 
business partners from contracting with new entrants, cause consumers to pay 
artificially inflated prices, and hurt innovation.3 This is true even when other firms 
know or suspect the patent of being invalid.4 The Federal Trade Commission 
(FTC) has noted that “improperly awarded patents may distort firms’ research 
choices and influence them to shun whole areas of R&D activity.”5 Moreover, the 
Federal Circuit has found that both the public at large and the patent system itself 
suffer because: 
A patent by its very nature is affected with a public interest. The far 
reaching social and economic consequences of a patent, therefore, give 
the public a paramount interest in seeing that patent monopolies spring 
from backgrounds free from fraud or other inequitable conduct and that 
such monopolies are kept within their legitimate scope. Where fraud is 
committed, injury to the public through a weakening of the Patent 
System is manifest.6 
In their book, The Patent Crisis and How the Courts Can Solve It, to which this 
symposium is dedicated, Professors Burk and Lemley note that “the patent system 
may actually do more harm than good to innovation, because the assertion and 
litigation of too many bad patents against companies that make innovative 
products ends up raising their costs and reducing their innovation more than the 
 
1. See John R. Allison & Mark A. Lemley, Empirical Evidence on the Validity of Litigated Patents, 26 
AIPLA Q.J. 185, 205 (1998) (forty-six percent of litigated patents were held invalid). 
2. FED. TRADE COMM’N, TO PROMOTE INNOVATION: THE PROPER BALANCE OF 
COMPETITION AND PATENT LAW AND POLICY, EXECUTIVE SUMMARY 9–10 (2003) [hereinafter 
FTC INNOVATION REPORT]. 
3. Christopher R. Leslie, The Anticompetitive Effects of Unenforced Invalid Patents, 91 MINN. L. REV. 
101 (2006). 
4. Id. at 166. 
5. FTC INNOVATION REPORT, supra note 2, at ch. 5, p. 2. 
6. Unitherm Food Sys., Inc. v. Swift-Eckrich, Inc., 375 F.3d 1341, 1361 (Fed. Cir. 2004) 
(quoting Norton v. Curtiss, 433 F.2d 779, 796 (C.C.P.A. 1970) (citations omitted)). 
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existence of those patents spurs new innovation.”7 
A patent can be invalid for many reasons. For example, in order for an 
invention to be patentable, it must be useful, novel, and nonobvious.8 Patent 
examiners review the prior art to determine whether a patent applicant’s invention 
is obvious. If the patent examiner misinterprets or is unaware of relevant prior art, 
a patent may issue that should not. When the defendant in an infringement action 
presents the prior art at trial, the patent would be invalidated.  
A patent may also be invalid because it violates one of the patent code’s 
statutory bars. Section 102(b) provides that a patent cannot issue if the invention 
was “in public use or on sale in this country, more than one year prior to the date 
of the application for patent in the United States.”9 The date one year before the 
application is filed is known as the “critical date.” Section 102(b) contains separate 
statutory bars to patentability—the public-use bar and the on-sale bar. 
The on-sale bar, in turn, includes two separate bars: sales and offers to sell. If 
an inventor has sold or offered to sell her invention more than one year before 
filing her patent application, the invention is no longer patentable. The on-sale bar 
provides the inventor a one-year grace period that Congress designed to recognize 
“the inventor’s right to control whether and when he may patent his invention” 
but also “to protect the public’s right to retain knowledge already in the public 
domain.”10 The on-sale bar “represents a balance of the policies of allowing the 
inventor a reasonable amount of time to ascertain the commercial value of an 
invention, while requiring prompt entry into the patent system after sales activity 
has begun.”11 Ultimately, the on-sale bar should expedite the dissemination of new 
inventions.12 
Section 102(b) contains statutory bars relating to public use and to sales 
activity. Although courts sometimes considered them together, the provisions are 
legally distinct.13 Circumstances exist where one bar may apply while the other 
 
7. DAN L. BURK & MARK A. LEMLEY, THE PATENT CRISIS AND HOW THE COURTS CAN 
SOLVE IT 30 (2009) (citations omitted). 
8. 35 U.S.C. §§ 101–103 (2006). 
9. 35 U.S.C. § 102(b) (2006). 
10. Pfaff v. Wells Elecs., Inc., 525 U.S. 55, 65 (1998) (noting that in 1939 Congress reduced 
the grace period from two years to one year). 
11. Seal-Flex, Inc. v. Athletic Track and Court Constr., 98 F.3d 1318, 1322 (Fed. Cir. 1996) 
(citation omitted). 
12. RCA Corp. v. Data Gen. Corp., 887 F.2d 1056, 1062 (Fed. Cir. 1989) (“One policy 
underlying the [on-sale] bar is to obtain widespread disclosure of new inventions to the public via 
patents as soon as possible.”); see also Timothy R. Holbrook, The More Things Change, the More They Stay 
the Same: Implications of Pfaff v. Wells Electronics, Inc. and the Quest for Predictability in the On-Sale Bar, 15 
BERKELEY TECH. L.J. 933, 939 (2000) (“[T]he on-sale bar promotes the public interest by requiring a 
prompt and widespread disclosure of new inventions to the public. Encouraging such disclosures and 
discouraging removal of information from the public domain presumably promotes greater 
technological development by adding to and maintaining the knowledge base in a given field.”). 
13. Handgards, Inc. v. Ethicon, Inc., 743 F.2d 1282, 1291 (9th Cir. 1984) (“Although it is clear 
that the ‘on sale’ and ‘in public use’ defenses are separate, many courts have evaluated them 
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does not. For example, an inventor may make public use of the invention without 
“any sale or offer to sell and, alternatively, there may be sales which neither the 
vendor nor the purchaser desires to make public but which nevertheless impose 
an obligation of the inventor to file his application within one year.”14 In short, a 
public use need not involve a sale and disqualifying sales can be nonpublic. 
Moreover, the two statutory bars have different focuses: “the public use bar 
focuses on the public’s reliance on an invention that is thought to be in the public 
domain, while the on-sale bar centers on any commercialization beyond the one 
year grace period.”15 The different purposes can affect the legal analysis of 
whether a particular bar has been triggered.16  
This Article focuses primarily on the on-sale bar because an applicant’s 
omissions of prior sales or offers that trigger the on-sale bar are particularly 
insidious because the patent examiner will most likely be unaware of this patent-
invalidating information.17 In its manual, the Patent Office hypothesizes that a 
patent examiner may have “personal knowledge” of the applicant’s sales activity.18 
This, however, seems very unlikely. In the vast majority of cases, patent examiners 
are dependent on applicants for such information. For example, patent examiners 
will not know about invalidating sales that were kept secret. Although the on-sale 
bar is designed to prevent an inventor from “remov[ing] existing knowledge from 
public use,”19 private sales trigger the on-sale bar.20 Even if the sales agreement 
requires that the invention be used “under conditions of secrecy,” the activity still 
counts for purposes of the on-sale bar.21 Yet patent examiners—and infringement 
 
together.”); Dart Indus., Inc. v. E.I. Du Pont De Nemours & Co., 489 F.2d 1359, 1365 (7th Cir. 
1973) (35 U.S.C. § 102(b) “contains several distinct bars to patentability, each of which relates to 
activity or disclosure more than one year prior to the date of the application. Two of these—the 
‘public use’ and the ‘on sale’ objections—are sometimes considered together although it is quite clear 
that either may apply when the other does not.”). 
14. Dart Indus., 489 F.2d at 1364 n.8. 
15. Honeywell Int’l, Inc. v. Universal Avionics Sys., Corp., 343 F. Supp. 2d 272, 290 (D. Del. 
2004). 
16. Id.  
17. See HERBERT HOVENKAMP, MARK JANIS, MARK LEMLEY & CHRISTOPHER LESLIE, IP 
AND ANTITRUST: AN ANALYSIS OF ANTITRUST PRINCIPLES APPLIED TO INTELLECTUAL 
PROPERTY LAW § 11.2 (2d ed. 2009) (“Indeed, the most common and insidious forms of fraud on 
the PTO are not affirmative statements, but the failure to disclose information, such as prior art 
references the PTO is unlikely to find on its own or information about the patentee’s own 
commercial activities. The latter is particularly likely to induce reliance, since the information is 
uniquely within the possession of the patentee.”). 
18. MANUAL OF PATENT EXAMINING PROCEDURE § 706.02(c) (8th ed., rev. 8, 2010) (“An 
applicant may make an admission, or submit evidence of sale of the invention or knowledge of the 
invention by others, or the examiner may have personal knowledge that the invention was sold by 
applicant or known by others in this country.”). 
19. Pfaff v. Wells Elecs., Inc., 525 U.S. 55, 64 (1998). 
20. Manufacturing Research Corp. v. Graybar Elec. Co., Inc., 679 F.2d 1355, 1362 (11th Cir. 
1982) (“[A]ny sale or offer, whether public or private, is enough to implicate the statutory bar.”). 
21. Hobbs v. U.S., Atomic Energy Comm’n, 451 F.2d 849, 860 (5th Cir. 1971). 
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defendants—are unlikely to know about the sale precisely because it is secret. 
Similarly, offers that were not accepted are particularly hard for patent 
examiners or infringement defendants to discover through their own research. It 
may be easy for patent applicants to conceal such offers because generally there is 
no public record of unsuccessful sales attempts. Because the on-sale bar applies to 
offers that are not actually received by the intended offeree,22 in this unusual 
circumstance, not even the offeree may know about the patent-invalidating offer. 
In order to determine whether one of the statutory bars should prohibit a 
patent from issuing, patent examiners perform research but also rely on 
information from the patent applicants. Patent applicants have a duty of candor. 
This means that “[t]hose who have applications pending with the Patent Office or 
who are parties to Patent Office proceedings have an uncompromising duty to 
report to it all facts concerning possible fraud or inequitableness underlying the 
applications in issue.”23 Unfortunately, the patent case law is rife with examples of 
patent applicants concealing prior art, public use, and sales activity before the 
critical date.  
In many ways, an applicant’s concealment of her prior sales activity is more 
threatening to the patent system than the omission of other types of material 
information. For example, sales activity is different than prior art that an 
examiner—or a competitor—is able to discover through independent research. 
Similarly, omissions of sales activity are harder to discover than failures to disclose 
public use, which must be “accessible to the public” or in the case of commercial 
exploitation “likely requires more than, for example, a secret offer for sale.”24 
In sum, it is vital that applicants disclose all material sales activity because it 
is too hard for examiners and competitors to uncover the relevant sales activity 
through their own investigations.25  
II. THE CONSEQUENCES OF CONCEALING SALES ACTIVITY 
Because the on-sale bar can render an invention unpatentable, patent 
applicants have an incentive to file their patent applications within a year of the 
critical date. Patent applicants who have delayed filing for more than one year 
after the critical date, unfortunately, have a powerful incentive to conceal all sales 
activity that might lead a patent examiner to reject their patent application under 
the on-sale bar. Both patent law and antitrust law have doctrines to deal with 
 
22. See MANUAL OF PATENT EXAMINING PROCEDURE § 2133.03(b) (8th ed., rev. 8, 2010) 
(“In fact, the offer need not even be actually received by a prospective purchaser.”) (citing Wende v. 
Horine, 225 F. 501 (7th Cir. 1915)). 
23. Precision Co. v. Automotive Co., 324 U.S. 806, 818 (1944). 
24. Invitrogen Corp. v. Biocrest Mfg., L.P., 424 F.3d 1374, 1380 (Fed. Cir. 2005). 
25. Christopher A. Cotropia, Modernizing Patent Law’s Inequitable Conduct Doctrine, 24 BERKELEY 
TECH. L.J. 723, 783 n.158 (2009) (“This information is unlikely to be found in any database available 
at the USPTO.”). 
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patent applicants who withhold material information regarding prior sales activity. 
This Part reviews those legal doctrines and discusses how they apply to questions 
involving the on-sale bar. 
A. Patent Law: The Inequitable Conduct Defense 
Patent law responds to a patent applicant’s failure to disclose sales activity 
through the inequitable conduct defense. The defense of inequitable conduct 
applies to situations when a patent applicant makes an affirmative 
misrepresentation of a material fact, or fails to disclose material information, or 
makes a submission of false material information coupled with an intent to 
deceive to the PTO.26 Thus, inequitable conduct entails two separate elements: 
materiality and intent.  
For decades, the Federal Circuit applied a sliding scale in evaluating these 
two elements. The court balanced the elements such that “[t]he more material the 
omission or misrepresentation, the less intent that must be shown to elicit a 
finding of inequitable conduct.”27 The Federal Circuit later added an additional 
step to this balancing analysis so that even if the infringement defendant can 
establish both materiality and intent by clear and convincing evidence, “the district 
court must still balance the equities to determine whether the applicant’s conduct 
before the PTO was egregious enough to warrant holding the entire patent 
unenforceable.”28  
In 2011, the Federal Circuit sitting en banc in Therasense v. Becton, Dickinson 
and Co.29 reevaluated its treatment of inequitable conduct. Although many issues 
divided the court, all of the judges agreed that in applying the inequitable conduct 
doctrine, the court should not employ a sliding scale.30 The elimination of the 
 
26. See Pharmacia Corp. v. Par Pharm., Inc., 417 F.3d 1369, 1373 (Fed. Cir. 2005) 
(“[I]nequitable conduct includes affirmative misrepresentation of a material fact, failure to disclose 
material information, or submission of false material information, coupled with an intent to 
deceive.”); see also Ferring B.V. v. Barr Labs., Inc., 437 F.3d 1181, 1190 (Fed. Cir. 2006) (“Even if an 
omission is found to be material, the omission must also be found to have been made with the intent 
to deceive.”). 
27. Impax Labs., Inc. v. Aventis Pharms. Inc., 468 F.3d 1366, 1375 (Fed. Cir. 2006); see also 
Critikon, Inc. v. Becton Dickinson Vascular Access, Inc., 120 F.3d 1253, 1256 (Fed. Cir. 1997) (“The 
more material the omission or the misrepresentation, the lower the level of intent required to establish 
inequitable conduct, and vice versa.”). 
28. Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., 537 F.3d 1357, 1365 (Fed. Cir. 2008) 
(“Thus, even if a threshold level of both materiality and intent to deceive are proven by clear and 
convincing evidence, the court may still decline to render the patent unenforceable.”) (citations 
omitted). 
29.  649 F.3d 1276 (Fed. Cir. 2011). 
30. Id. at 1290 (“A district court should not use a ‘sliding scale,’ where a weak showing of 
intent may be found sufficient based on a strong showing of materiality, and vice versa.”); see also id. at 
1288 (condemning sliding scale because it “conflated, and diluted, the standards for both intent and 
materiality”); Id. at 1302 (Bryson, J., dissenting) (“[T]here should be no ‘sliding scale’ whereby a strong 
showing as to one element can make up for weaker proof as to the other.”). 
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sliding scale, however, did not render the materiality element completely 
extraneous to the intent inquiry. Although “a district court may not infer intent 
solely from materiality,”31 materiality is still relevant in determining intent. District 
courts often must infer deceptive intent from circumstantial evidence because 
direct evidence is rarely available.32 The degree of materiality of a 
misrepresentation or omission is one form of circumstantial evidence that a 
district court may rely upon.33 
The inequitable conduct doctrine is a defense employed by defendants in 
patent infringement litigation. The defendant carries the burden of proof and 
must prove both elements—materiality and intent—with clear and convincing 
evidence. If the defendant can prove that the patent applicant engaged in 
inequitable conduct when prosecuting its patent, then the patent is 
unenforceable.34 Even if the inequitable conduct only relates to one claim, all of 
the patent claims in the application are unenforceable.35 The unenforceability may 
even expand to related patent applications.36 If the defendant prevails by proving 
that the patentee engaged in inequitable conduct, the case may be deemed 
“exceptional,”37 entitling the defendant to a fee reward, “which can reach well into 
the seven figure range.”38  
 
31. Id. at 1290. 
32. Id. 
33. See id. at 1297 n.1 (O’Malley, J., concurring in part and dissenting in part) (“the majority 
does not hold that it is impermissible for a court to consider the level of materiality as circumstantial 
evidence in its intent analysis.”); see also id. at 1304 n.1 (Bryson, J., dissenting) (“It is important to 
distinguish between relaxing the required proof of intent if the proof of materiality is strong, which is 
impermissible, as opposed to considering the degree of materiality as relevant to the issue of intent, 
which is appropriate . . . .”) (citations omitted). 
34. See Digital Control, Inc. v. Charles Mach. Works, 437 F.3d 1309, 1313 (Fed. Cir. 2006) 
(“[A] patent may be rendered unenforceable for inequitable conduct if an applicant, with intent to 
mislead or deceive the examiner, fails to disclose material information or submits materially false 
information to the PTO during prosecution.”). 
35. Kingsdown Med. Consultants, Ltd. v. Hollister, Inc., 863 F.2d 867, 877 (Fed. Cir. 1988) 
(en banc) (“When a court has finally determined that inequitable conduct occurred in relation to one 
or more claims during prosecution of the patent application, the entire patent is rendered 
unenforceable.”); Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., 537 F.3d 1357, 1365 (Fed. Cir. 
2008) (highlighting the penalty for inequitable conduct as so severe as to result in “the loss of the 
entire patent even where every claim clearly meets every requirement of patentability.”). This is 
important for on-sale bar purposes because the on-sale bar is evaluated on a claim-by-claim basis; a 
particular sale may invalidate some claims in a patent application but not others. Allen Engr. Corp. v. 
Bartell Indus., Inc., 299 F.3d 1336, 1353 (Fed. Cir. 2002). 
36. See Fox Indus., Inc. v. Structural Pres. Sys., Inc., 922 F.2d 801, 803–04 (Fed. Cir. 1990) 
(stating that inequitable conduct “may render unenforceable all claims which eventually issue from the 
same or a related application”); Cotropia, supra note 25, at 725 (citing Consol. Aluminum Corp. v. 
Foseco Int’l, Ltd., 910 F.2d 804, 812 (Fed. Cir. 1990)) (“If there is a pattern of inequitable conduct, 
unenforceability can transfer from one patent to another.”). 
37. Brasseler, U.S.A. I, L.P. v. Stryker Sales Corp., 267 F.3d 1370, 1380 (Fed. Cir. 2001) (“The 
prevailing party may prove the existence of an exceptional case by showing: inequitable conduct 
before the PTO . . . .”). 
38. Cotropia, supra note 25, at 764–65. 
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In sum, a patent applicant’s failure to disclose material information regarding 
its sales activity—both offers and actual sales—can constitute inequitable conduct 
if the applicant withholds the information with an intent to deceive the patent 
examiner. This would render the patent unenforceable, even if the patent would 
have issued if the patent examiner had known about the sales information.  
B. Antitrust Implications: Walker Process Liability 
A patent applicant’s failure to disclose sales activity to the PTO can also 
create antitrust liability in some circumstances. Section 2 of the Sherman Act 
condemns illegal monopolization.39 It is not illegal to possess a monopoly; rather 
it is illegal to acquire or maintain a monopoly through anticompetitive conduct. In 
order to establish illegal monopolization, a plaintiff must prove two elements. 
First, the defendant possesses monopoly power in a relevant market.40 Second, the 
plaintiff must prove the defendant’s “willful acquisition or maintenance of that 
power as distinguished from growth or development as a consequence of a 
superior product, business acumen, or historic accident.”41  
This second element is often called “monopoly conduct.” The Sherman Act 
does not define monopoly conduct. Instead, through the common law process, 
courts have characterized some anticompetitive behavior as monopoly conduct. 
Most importantly for our purposes, the Supreme Court in Walker Process Equip., 
Inc. v. Food Mach. & Chem. Corp.42 held that enforcing a patent acquired through 
fraud on the PTO constitutes monopoly conduct. The Federal Circuit, in turn, has 
defined patent fraud incorporating the same elements as common law fraud: “(1) 
that a false representation of a material fact was made, (2) with the intent to 
deceive, (3) which induced the deceived party to act in justifiable reliance on the 
misrepresentation, and (4) which caused injury that would not otherwise have 
occurred.”43 Thus, like inequitable conduct, Walker Process liability requires 
materiality and intent. 
Walker Process claims are often brought as counterclaims by defendants in 
patent infringement litigation. The counterclaimant can establish antitrust liability 
if she can prove that the patentee possesses monopoly power and either acquired 
or is maintaining that power by enforcing a fraudulent patent.44 Unlike the 
 
39. 15 U.S.C. § 2 (2006). 
40. U.S. v. Grinnell Corp., 384 U.S. 563, 570 (1966). 
41. Id. at 570–71. A private plaintiff must also prove that it has suffered antitrust injury. 
42. 382 U.S. 172 (1965). 
43. C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1364 (Fed. Cir. 1998); In re Spalding Sports 
Worldwide, Inc., 203 F.3d 800, 807 (Fed. Cir. 2000) (defining patent fraud as “(1) a representation of 
a material fact, (2) the falsity of that representation, (3) the intent to deceive or, at least, a state of 
mind so reckless as to the consequences that it is held to be the equivalent of intent (scienter), (4) a 
justifiable reliance upon the misrepresentation by the party deceived which induces him to act 
thereon, and (5) injury to the party deceived as a result of his reliance on the misrepresentation.”). 
44. See Christopher R. Leslie, Patents of Damocles, 83 IND. L.J. 133 (2008) (advocating a broader 
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inequitable conduct defense, a Walker Process claim is a cause of action and the 
successful antitrust claimant is entitled to damages. Whatever actual damages she 
can prove are automatically trebled. 
C. The Intent to Deceive 
Both the patent law defense of inequitable conduct and the antitrust cause of 
action for monopolization through patent fraud require the party with the burden 
of proof to show that the patent applicant misrepresented or omitted material 
information with an intent to deceive. This Section critiques the Federal Circuit’s 
intent-to-deceive analysis from two different perspectives. First, the Federal 
Circuit improperly treats the intent to deceive for Walker Process fraud purposes 
more harshly than it treats that same element for inequitable conduct purposes. 
Second, comparing Walker Process litigation in which Federal Circuit found intent 
to deceive and litigation in which it did not reveals a judicial focus on distinctions 
that should not make a difference.  
1. Different Standards for the Intent to Deceive for Inequitable Conduct and Walker Process 
Purposes 
Although both inequitable conduct and Walker Process claims require proof of 
intent to deceive the PTO, the Federal Circuit applies disparate analysis to the 
deceptive intent issue depending on which legal doctrine it is evaluating. In Dippin’ 
Dots, Inc. v. Mosey, the plaintiff had a patent covering “a process for making a form 
of cryogenically prepared novelty ice cream product.”45 Plaintiff, Dippin’ Dots, 
Inc. (DDI), sold “beaded ice cream” to over 800 customers at a public festival 
before the critical date. The patentee did not disclose the sales to the PTO. The 
district judge ruled that the patentee had engaged in inequitable conduct and thus 
could not enforce its patent against the alleged infringer. The jury also found that 
the patentee had engaged in patent fraud and, after finding the other elements of 
illegal monopolization present, ruled for the alleged infringer on its antitrust 
counterclaim.  
The patentee appealed to the Federal Circuit. The appellate panel affirmed 
the ruling on inequitable conduct. Applying the two-element test for the 
inequitable conduct defense, the court held that the first element of “materiality[] 
is clearly met here.”46 The sales activity at the public fair was clearly something 
that the reasonable patent examiner would want to know about when considering 
the on-sale bar. The second element of intent was a more contentious issue. In the 
end, the court upheld the judge’s finding that DDI intended to deceive the PTO 
because  
 
definition of patent enforcement for Walker Process purposes). 
45. 476 F.3d 1337, 1340 (Fed. Cir. 2007). 
46. Id. at 1345. 
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[w]hile DDI wholly neglected to disclose the Festival Market sales to the 
PTO, it enthusiastically touted sales made after the critical date as 
evidence of the commercial appeal of its process. That combination of 
action and omission permits an inference of the minimum, threshold 
level of intent required for inequitable conduct.47  
Ultimately, strong evidence regarding materiality compensated for relatively weak 
intent evidence.48 
The Federal Circuit, however, reversed the jury verdict on the antitrust 
counterclaim. The court began its discussion by holding that “[t]o demonstrate 
Walker Process fraud, a claimant must make higher threshold showings of both 
materiality and intent than are required to show inequitable conduct.”49 The court 
again upheld the materiality finding because “the evidence supports a finding that 
the patent would not have issued if DDI had disclosed the Festival Market sales to 
the PTO.”50 
The court then held that the antitrust counterclaimant could not prove that 
DDI withheld this material information of its sales activity with an intent to 
deceive. The court reasoned that the intent evidence against DDI was insufficient 
because all the antitrust plaintiff could show was that the patentee omitted 
material information and that the jury disbelieved the patentee’s explanation for 
why it concealed the prior sales activity.51 Reasoning that this knowing omission 
of a material fact coupled with a pretextual explanation was not enough to show 
deceptive intent, the Federal Circuit held that no reasonable jury could find Walker 
Process fraud and reversed the jury verdict on the antitrust counterclaim.52 
The Federal Circuit’s disparate treatment of deceptive intent for inequitable 
conduct and antitrust purposes is perplexing. The court held that there was 
sufficient evidence for the judge to find intent to deceive PTO for inequitable 
conduct purposes, but that no reasonable jury could have found intent to deceive 
PTO for Walker Process fraud purposes. This is puzzling because no patent 
applicant intends to deceive the PTO for inequitable conduct purposes, but not 
for Walker Process purposes. The patent applicant’s intent to deceive is effectively 
the same with respect to inequitable conduct and fraud. In both instances, the 
patent applicant is withholding information in an effort to get the Patent Office to 
approve a patent that is as broad as possible.  
Through its holding in Dippin’ Dots, the Federal Circuit essentially asserts that 
the quantum of evidence is different between inequitable conduct and fraud. But it 
 
47. Id. at 1346. 
48. The court employed the sliding scale that it has since rejected in Therasense. 
49.  Dippin’ Dots, 476 F.3d at 1346. 
50. Id. at 1347. 
51. Id. at 1348 (“That intent cannot be shown merely from the absence of evidence which 
would come about from the jury’s discounting DDI’s explanation.”). 
52. Id. (“[T]hey must prove deceptive intent independently. The defendants have not done so 
here to the extent necessary for a reasonable jury to find Walker Process fraud.”). 
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articulates no evidentiary standards to explain this holding. The Federal Circuit 
does not define how the intent to deceive the PTO in order to commit inequitable 
conduct is different than the intent to deceive the PTO in order to commit Walker 
Process fraud. Yet, the court has imposed two different legal tests for these two 
purposes, albeit without actually stating what the two different tests are. The 
Dippin’ Dots distinction between deceptive intent for inequitable conduct and 
deceptive intent for antitrust fraud makes little sense. 
2. Defining the Intent to Deceive by Comparing Walker Process Decisions 
In reversing the jury verdict in Dippin’ Dots, the Federal Circuit directed 
litigants to its opinion in Nobelpharma AB v. Implant Innovations, Inc.53 “as a good 
example of the sort of facts that do prove Walker Process fraud by omission.”54 In 
Nobelpharma, the inventor had drafted a Swedish patent application that included a 
citation to a book that the patentee had written years earlier.55 Before the 
application was filed in Sweden, the patentee removed all references to the book 
and also omitted any citation to the book in its American patent application. An 
American patent issued. When discovered later, however, the book was held to 
anticipate the patent and thus the patent was invalid.56 When asked at trial why he 
deleted references to the book from the draft patent application, the patent agent 
“could not explain, even in retrospect” why he had done so.57 Distinguishing its 
holding in Nobelpharma, the Dippin’ Dots panel noted that the earlier panel had 
“found that the evidence of actual deletion by the patent agent gave the jury 
reasonable ground to find intent to defraud by the patentees.”58 The Dippin’ Dots 
panel then sought to distinguish the facts before it from those in Nobelpharma by 
asserting that “[t]here is no similarly strong evidence that the omission in this case 
was fraudulent.”59 
Although the Dippin’ Dots court saw the facts of Nobelpharma as markedly 
different, the pertinent facts are essentially the same. In both cases, the applicant 
withheld clearly material information. The patentee in Nobelpharma omitted a 
reference to a book that was relevant prior art. The patentee in Dippin’ Dots 
omitted a reference to sales that made the invention unpatentable under the on-
sale bar.  
In both cases, the applicant considered disclosing information but ultimately 
decided against it. The patentee in Nobelpharma initially cited the book in the draft 
of a foreign patent application, but later removed the reference before filing either 
 
53. 141 F.3d 1059 (Fed. Cir. 1998). 
54. Dippin’ Dots, 476 F.3d at 1348. 
55. 141 F.3d at 1062. 
56. Id. at 1072. 
57. Id. 
58. Dippin’ Dots, 476 F.3d at 1348. 
59. Id.  
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that application or the American one. This act of deletion proves nothing except 
that the applicant was considering including the information and ultimately 
decided against its inclusion. The patent applicant made a judgment call and 
decided to omit the reference. The patent applicant in Dippin’ Dots made a similar 
judgment call—it considered including a reference to the 800 sales and decided 
not to. That decision, according to the Federal Circuit, was wrong. If Dippin’ 
Dots had included a reference to the 800 sales on an internal draft version of its 
patent application and then decided that the disclosure was not necessary and thus 
removed it, not a single relevant fact would have changed. Yet, under Nobelpharma, 
Dippin’ Dots would have committed fraud. 
In neither case did the antitrust plaintiff have direct evidence of intent to 
deceive. In Nobelpharma, the court allowed deceptive intent to be inferred from the 
deletion of a material reference. No direct evidence showed that the patent agent 
removed the reference to the book in order to deceive the various patent offices. 
Similarly, the patent infringement defendants in Dippin’ Dots lacked direct evidence 
of deceptive intent. 
In sum, the underlying misconduct is the same in the two cases. Although 
the Federal Circuit in Dippin’ Dots sought to distinguish Nobelpharma, this is a 
distinction without a meaningful difference. In both cases: the patentee knew 
material information; the patentee withheld the material information; no direct 
evidence of intent to deceive existed; and the jury inferred deceptive intent from 
the omission and the lack of a reasonable explanation of that omission. The most 
important difference between Dippin’ Dots and Nobelpharma is that in Nobelpharma 
the Federal Circuit affirmed the jury verdict finding Walker Process fraud and in 
Dippin’ Dots the Federal Circuit held that there was insufficient evidence to find 
fraud. This difference in legal outcomes based on similar facts illustrates the 
confusion surrounding how to prove deceptive intent for Walker Process purposes. 
When these two decisions are read in tandem, the ultimate lesson is a 
roadmap for patent fraud. Any patentee who wants to avoid Walker Process liability 
while omitting material information should simply be sure to not put the 
information into a draft application and then subsequently remove it. If the 
Federal Circuit continues to limit Nobelpharma to its facts, it will be exceedingly 
difficult for antitrust plaintiffs to prove Walker Process fraud even when they 
convince a jury. After all, it is the rare case that an applicant puts damning 
information in a draft, removes it, and leaves a paper trail so that infringement 
defendants and federal judges can confirm the inclusion and subsequent 
subtraction.60 
 
60. While other forms of evidence to prove fraudulent intent are possible, patent applicants 
rarely have reason to memorialize their deceptive intent. 
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D. The Problem Post-Dippin’ Dots 
Through the manipulation of the intent element, the Federal Circuit has 
made it exceedingly difficult for Walker Process plaintiffs to prevail. The Federal 
Circuit is increasingly reluctant to find inequitable conduct.61 Various judges of the 
court have referred to the defense as a “plague” and an “atomic bomb.”62 While 
these characterizations are suspect,63 they affect Walker Process doctrine because 
the court makes it impossible to prove Walker Process fraud in the absence of 
inequitable conduct. Yet, as shown above, the Federal Circuit seems too reluctant 
to find deceptive intent for Walker Process fraud even when it finds deceptive intent 
for inequitable conduct purposes. More suspect, the Federal Circuit has artificially 
distinguished a case in which it affirmed a jury verdict finding Walker Process fraud 
and antitrust liability. Ultimately, the Federal Circuit is quick to label omissions of 
information to be the product of honest judgment calls that applicants must 
make.64 
The Federal Circuit’s impulse to minimize the significance of omissions in 
Walker Process cases is misguided. Omissions should be taken more seriously. The 
Patent Office has weakened disclosure requirements since the Supreme Court’s 
opinion in Walker Process. While the patentee in Walker Process had to swear that it 
neither knew nor believed that a statutory bar applied, the Federal Circuit has 
explained that “[t]he PTO does not currently require inventors to file a sworn 
statement regarding such knowledge or belief.”65 That is an important 
difference—omissions during the Walker Process era operated as misstatements 
because the applicant affirmatively swore that nothing was omitted. Ideally, this 
should be a distinction without a difference. After all, the Federal Circuit has 
opined that “a fraudulent omission can be just as reprehensible as a fraudulent 
misrepresentation.”66 In reality, however, the Federal Circuit treats 
 
61. See Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., 537 F.3d 1357, 1366 (Fed. Cir. 2008) 
(“[C]ourts must be vigilant in not permitting the [inequitable conduct] defense to be applied too 
lightly.”); id. at 1365 (“[T]he need to strictly enforce the burden of proof and elevated standard of 
proof in the inequitable conduct context is paramount because the penalty for inequitable conduct is 
so severe, the loss of the entire patent even where every claim clearly meets every requirement of 
patentability.”). 
62. Aventis Pharma S.A. v. Amphastar Pharm., Inc., 525 F.3d 1334, 1349 (Fed. Cir. 2008) 
(Rader, J., dissenting). 
63. Benjamin Brown, Inequitable Conduct: A Standard in Motion, 19 FORDHAM INTELL. PROP. 
MEDIA & ENT. L.J. 593, 626 (2009) (“[I]nequitable conduct is not a plague upon the courts but, 
rather, a defense that is pled in a mere 20% of patent infringement cases.”). 
64. See C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1365 (Fed. Cir. 1998) (“Deceptive 
intent is not inferred simply because information was in existence that was not presented to the 
examiner; and indeed, it is notable that in the usual course of patent prosecution many choices are 
made, recognizing the complexity of inventions, the virtually unlimited sources of information, and 
the burdens of patent examination.”).  
65. Nobelpharma AB v. Implant Innovations, Inc., 141 F.3d 1059, 1069 n.6 (Fed. Cir. 1998) 
(citing 35 U.S.C § 115 (1994); 37 C.F.R. § 1.63 (1996)). 
66. Nobelpharma, 141 F.3d at 1070. 
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misrepresentations more harshly than omissions in that the court is more likely to 
infer fraudulent intent from a misrepresentation than from an omission. For 
example, the Dippin’ Dots court held that  
to find a prosecution omission fraudulent there must be evidence of 
intent separable from the simple fact of the omission. A false or clearly 
misleading prosecution statement may permit an inference that the 
statement was made with deceptive intent. For instance, evidence may 
establish that a patent applicant knew one fact and presented another, 
thus allowing the fact-finder to conclude that the applicant intended by 
the misrepresentation to deceive the examiner.67 
This distinction is artificial because the patentee in this case “knew one fact”—
that it had made sales of the patented product before the critical date—“and 
presented another,” namely, that no such sales occurred. The fact that the 
patentee accomplished its deceit through an omission instead of an affirmative 
statement is beside the point. The harm caused by the omission is the same as the 
harm caused by a misrepresentation. 
III. HARMONIZING THE DEFINITION OF DECEPTIVE INTENT  
In theory, the applicants’ duty of candor should ensure that applicants 
disclose all material information concerning their sales and offers. At its heart, the 
inequitable conduct doctrine primarily serves a disclosure function because if the 
applicant fails to disclose material information with deceptive intent, then the 
patent becomes unenforceable.68 Antitrust liability provides an even more 
powerful incentive for patent applicants to disclose all material sales information 
by creating a cause of action for those who suffer injury caused by an illegal 
monopoly acquired through patent fraud. 
Section Two showed how the Federal Circuit has made it difficult for 
antitrust plaintiffs to prove intent to deceive in the context of omissions. The 
Federal Circuit is loath to infer deceptive intent from omissions for Walker Process 
purposes. This is odd given that the court is willing to do so when applying the 
inequitable conduct doctrine.  
This Section argues that courts should not treat intent to deceive more 
harshly for Walker Process purposes than for inequitable conduct purposes. This is 
especially true in the context of omitting sales activity because direct evidence of 
fraudulent intent generally does not exist. If courts systematically err on the side of 
treating omissions as innocent mistakes, patent applicants have a powerful 
incentive to omit invalidating sales from their patent applications. When 
 
67. Dippin’ Dots, 476 F.3d at 1347; see also id. (“That is not the case with an omission, which 
could happen for any number of nonfraudulent reasons—the applicant could have had a good-faith 
belief that disclosure was not necessary, or simply have forgotten to make the required disclosure.”). 
68. Cotropia, supra note 25, at 753 (“The inequitable conduct doctrine is a disclosure doctrine, 
which, by its inherent nature, creates a flow of information from the applicant to the USPTO.”). 
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applicants succumb, invalid patents result. 
There must be consequences for withholding information from the PTO 
and those consequences must outweigh the expected value of the willful 
concealment.69 This cannot occur unless fraudulent conduct is accurately 
recognized and properly penalized. Only then can patent fraud be optimally 
deterred. One major impediment to deterring patent fraud by omission is the 
Federal Circuit’s interpretation of deceptive intent for Walker Process purposes. 
A. Inferring Deceptive Intent from Omissions 
Proving intent to deceive the PTO is inherently complicated. Patent 
applicants do not generally commit their fraudulent intentions to paper. They do 
not document their plans to deceive the Patent Office and its examiners. 
Consequently, the Federal Circuit has “held that because direct evidence of 
deceptive intent is rarely available, such intent can be inferred from indirect and 
circumstantial evidence.”70 In general, however, deceptive intent may not be 
inferred from the omission alone.71  
The Federal Circuit has never actually defined fraud by omission. It has 
presented examples of it, as in Nobelpharma. But this is a far cry from a functional 
test for detecting and deterring this species of fraud. Instead, intent is proven 
through inferences. Because intent to deceive must be inferred from surrounding 
circumstances,72 the issue becomes what circumstantial evidence gives rise to 
inferences of dishonesty. There is no clarity on this issue.73  
One way to bring more rationality to the definition of deceptive intent for 
Walker Process purposes is to utilize the pre-Therasense approach used by the Federal 
Circuit when analyzing deceptive intent for inequitable conduct purposes. On 
numerous occasions, the Federal Circuit has inferred deceptive intent when the 
patent applicant withheld information that it knew or should have known was 
 
69. Invalidity alone is an insufficient deterrent if the patent should not have issued in the first 
place. 
70. Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., 537 F.3d 1357, 1366 (Fed. Cir. 2008) 
(citing Cargill, Inc. v. Canbra Foods, Ltd., 476 F.3d 1359, 1364 (Fed. Cir. 2007)); see also Impax Labs., 
Inc. v. Aventis Pharm., Inc., 468 F.3d 1366, 1375 (Fed. Cir. 2006) (Deceptive intent “rarely can be, 
and need not be, proven by direct evidence.”); Molins PLC v. Textron, 48 F.3d 1172, 1180–81 (Fed. 
Cir. 1995) (“Generally, intent must be inferred from the facts and circumstances surrounding the 
applicant’s conduct.”). 
71. C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1365 (Fed. Cir. 1998). 
72. Aventis Pharma S.A. v. Amphastar Pharm., Inc., 525 F.3d 1334, 1344 (Fed. Cir. 2008) 
(“Given that direct evidence is often unavailable, intent is generally inferred from surrounding facts 
and circumstances.”). 
73. Terrence P. McMahon & Mary B. Boyle, The “Elevated Evidentiary Burden” to Prove Inequitable 
Conduct, 10 SEDONA CONF. J. 197, 201 (2009) (“This general issue—under what circumstances may 
deceptive intent be inferred—remains a source of uncertainty in the law and, apparently, conflict 
between different panels in the Federal Circuit.”). 
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material, and failed to provide a credible explanation for the omission.74 For 
example, in inequitable conduct cases the Federal Circuit has inferred intent from 
omission, reasoning that “[t]he high materiality of the withheld prior art coupled 
with the lack of ‘a credible explanation for the nondisclosure’ led us to conclude 
that the district court had not committed clear error by inferring an intent to 
deceive.”75  
A similar approach should be employed in Walker Process cases. Courts 
should treat materiality of the omitted information as circumstantial evidence of 
deceptive intent for Walker Process purposes. Part of the circumstantial evidence 
from which intent may be inferred should include the materiality of the omitted 
information.76 Even in the absence of a sliding scale, the materiality of the 
omission is a relevant piece of circumstantial evidence that a reasonable jury could 
use to infer deceptive intent. Omitting sales information that is indisputably 
material—i.e., a sale that clearly invalidates the patent under the on-sale bar—is 
more suspicious than omitting information that is only arguably patent 
invalidating. The more material the omission, the more appropriate the inference 
of bad intent. 
If a patent applicant knows that sales activity has occurred (whether or not it 
constitutes a sale or offer before the critical date) and the applicant knows that he 
must disclose that information to the PTO, the failure to disclose is evidence of 
intent. This is essentially the approach that the Federal Circuit took in Unitherm 
Food Systems, Inc. v. Swift-Eckrich, Inc.,77 in which the judges inferred deceptive intent 
from the applicant’s omission of a fact despite its knowledge that the fact was 
material.78 With respect to deceptive intent regarding misstatements, courts have 
held that “the fact of misrepresentation coupled with proof that the party making 
it had knowledge of its falsity is enough to warrant drawing the inference that 
there was a fraudulent intent.”79 Similarly, the withholding of material information 
with the knowledge that the patent applicant is required to produce it should 
suffice to provide a legal basis for inferring an intent to deceive.  
B. Defining Deceptive Intent in a Manner that Optimizes Disclosure 
A less narrow definition of deceptive intent for Walker Process purposes 
 
74. See, e.g., Monsanto Co. v. Bayer Biosci. N.V., 514 F.3d 1229, 1241 (Fed. Cir. 2008) 
(Gajarsa, J.) (“[A]bsent a credible reason for withholding the information, intent may be inferred 
where a patent applicant knew, or should have known, that withheld information would be material 
to the PTO’s consideration of the patent application.”). 
75. McKesson Info. Solutions, Inc. v. Bridge Med., Inc., 487 F.3d 897, 916 (Fed Cir. 2007) 
(discussing Bruno Indep. Living Aids, Inc. v. Acorn Mobility Servs., Ltd., 394 F.3d 1348 (Fed. Cir. 
2005)). 
76. This survives Therasense.  
77. 375 F.3d 1341 (Fed. Cir. 2004). 
78. Id. at 1360. 
79. Norton v. Curtiss, 433 F.2d 779, 795–96 (C.C.P.A. 1970). 
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should increase disclosures of material information. A rational patent applicant 
deciding whether to include or omit a reference to particular sales activity must 
consider the costs and benefits of omission. If the omission is deemed material 
and deceptive intent is found, the inequitable conduct defense would render the 
patent unenforceable. If the information is sufficiently material that the patent 
would not have issued if it had been disclosed, then the patent applicant may 
conclude that the omission is rational. If the penalty for omission is losing a patent 
that would not have issued but for the omission, then omission is cost-beneficial 
given the possibility that the misconduct will not be discovered. In contrast, if the 
penalty for omitting patent-invalidating information is actual damages—which are 
trebled—awarded to an antitrust plaintiff, then omission is less likely to be cost-
beneficial and disclosure is more likely.  
To perform their jobs effectively, patent examiners must have access to all 
material information.80 Otherwise, patent quality suffers.81 In many cases, in order 
to apply the on-sale bar properly, patent examiners must request additional 
information from the applicant.82 This, however, assumes that the patent examiner 
has enough information to appreciate that further questioning is necessary. 
Unfortunately, patent examiners are generally dependent on patent applicants to 
provide the relevant information regarding sales activity in the first place.83 For 
example, in Dippin’ Dots, the examiner could not ask specific questions about the 
800 sales at the public festival because she was unaware of them. 
While holders of valid patents have the right to exclude infringing 
competitors from the market, even invalid patents can deter market entry.84 This 
results in higher prices, lower output, and market inefficiency. While competitors 
could theoretically enter the market if they thought a patent were invalid, rival 
firms sometimes do not have access to the information necessary to make an 
informed decision to enter a market despite the presence of a patent.85  
Proper disclosure in patent applications is important to help markets 
function. More disclosure during the patent application process can inform rivals’ 
market entry decisions after the patent issues. Disclosure helps competitors 
evaluate patent validity when deciding whether to enter the market in a manner 
 
80. Doug Lichtman & Mark A. Lemley, Rethinking Patent Law’s Presumption of Validity, 60 STAN. 
L. REV. 45, 46 (2007) (“Information is a second significant impediment to PTO review.”). 
81. Cotropia, supra note 25, at 748 (“The assurance of a good patent quality is all about 
information—both access to it and time for the examiners to use it.”). 
82. See MANUAL OF PATENT EXAMINING PROCEDURE § 706.2(c) (8th ed., rev. 8, 2010); see 
also Ferring B.V. v. Barr Labs., Inc., 437 F.3d 1181, 1187 (“[E]xaminers have broad authority to 
request information that they deem relevant to the issue of patentability.”). 
83. See Cotropia, supra note 25, at 754 (“Patent examiners also must rely on applicants to 
inform them of potential offers to sale, conference presentations, test data, and product brochures 
regarding the invention.”). 
84. Leslie, supra note 3, at 113–39.  
85. See Cotropia, supra note 25, at 754 n.156 (“A vast amount of inventor specific material, or 
hard to find material in a given field, is just not accessible.”). 
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that appears to infringe the patent. When competitors have more information, it 
adds predictability.86 Once a firm receives a cease-and-desist letter, it can more 
easily evaluate the validity of the patent that it is accused of infringing and make a 
more informed decision whether to cease/desist or to continue “infringing.” 
Information in the patent application is particularly important in this scenario 
because the accused infringer does not yet have access to discovery. 
Additionally, increased disclosure could render infringement litigation more 
efficient. After a firm is sued for infringement, it can make a more informed 
decision whether to settle or litigate. Because the information is already in the file, 
alleged infringers will have access to the information and be able to focus 
discovery on determining whether the sales at issue are disqualifying ones and to 
ask more pointed questions about it during depositions and at trial. Infringement 
defendants would have more information to make an appropriate on-sale bar 
defense. At a minimum, it informs and guides the infringement defendant’s 
discovery efforts in the litigation.  
Having additional information in the patent applications would increase 
transparency.87 If published patents included when and where the first sale (or 
offer for sale) took place, those with contrary knowledge would be more likely to 
expose an earlier invalidating sale. Cleaning up invalid patents improves the 
efficiency of the overall patent system.88  
C. Harmonizing Deceptive Intent for Inequitable Conduct and Walker Process Purposes, 
While Keeping the Doctrines Distinct 
Antitrust liability based on fraudulently procured patents and the defense of 
inequitable conduct are two separate legal doctrines. In his concurring opinion in 
Walker Process, Justice Harlan made a point of distinguishing between misconduct 
by a patent applicant that gives rise to antitrust liability and misbehavior that falls 
outside of antitrust’s purview.89 The majority opinion, he noted, sought to 
 
86. Holbrook, supra note 12, at 945 (“Competitors similarly suffered because they could not, 
with certainty, form opinions regarding the validity of a patent when deciding whether to sell a 
competing and perhaps infringing product.”). Scholars have argued that firms in some industries do 
not bother to read patents before entering the market because knowing about the patent increases the 
risk of being found to have willfully infringed, which would increase the damages for infringement. 
Mark A. Lemley & Ragesh K. Tangri, Ending Patent Law’s Willfulness Game, 18 BERKELEY TECH. L.J. 
1085 (2003). While this may be true in some industries, in others, firms do investigate patents before 
entering the market. 
87. See JAMES BESSEN & MICHAEL JAMES MEURER, PATENT FAILURE: HOW JUDGES, 
BUREAUCRATS, AND LAWYERS PUT INNOVATORS AT RISK 242 (2008) (“It has become a virtual 
cliché among policymakers to ever and always emphasize the superiority of transparent government 
policies. This is certainly true for patents and other property rights.”). 
88. Christopher R. Leslie, Antitrust and Patent Law as Component Parts of Innovation Policy, 34 J. 
CORP. L. 1259, 1270–72 (2009). 
89. Walker Process Equip., Inc. v. Food Machinery Corp, 382 U.S. 172, 180 (1965) (“[T]o 
hold, as we do not, that private antitrust suits might also reach monopolies practiced under patents 
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“achiev[e] a suitable accommodation in this area between the differing policies of 
the patent and antitrust laws.”90 Antitrust law reached those “patent[s] procured 
by deliberate fraud.”91 Misconduct by patent applicants involving nonfraudulently 
procured patents was left to patent law. To conflate Walker Process fraud with other 
lesser forms of patent invalidity could chill innovation. 
Some may worry that having a more unified definition of deceptive intent 
risks conflating inequitable conduct and Walker Process liability. The doctrines 
should be kept separate because the inequitable conduct defense is broader than 
Walker Process fraud and reaches more forms of misconduct.92 Further, Walker 
Process liability imposes a greater penalty in the form of treble damages93 than the 
inequitable conduct defense, whose remedy is unenforceability of the affected 
patent. As the Federal Circuit has noted, “[s]imply put, Walker Process fraud is a 
more serious offense than inequitable conduct.”94  
The Federal Circuit’s primary flaw in Dippin’ Dots was to suggest that the 
intent requirement is what separates inequitable conduct from fraud. The intent to 
deceive for both doctrines is essentially the same. The patent applicant intends to 
conceal damaging information from the patent examiner because of the fear that 
the examiner will either reject the application or narrow the reach of any patent 
that eventually issues. The patent applicant does not intend to commit inequitable 
conduct while not committing Walker Process fraud. The patent applicant intends 
to deceive, period.  
What separated inequitable conduct from fraud at the time of the Dippin’ 
Dots decision was not the intent requirement—it was the materiality requirement. 
The materiality standards for inequitable conduct and fraud were significantly 
different. A fact was “material” for the purposes of inequitable conduct if a 
“reasonable examiner would consider it important in deciding whether to allow 
the application to issue as a patent.”95 A statement could be material for the 
 
that for one reason or another may turn out to be voidable under one or more of the numerous 
technicalities attending the issuance of a patent, might well chill the disclosure of inventions through 
the obtaining of a patent because of fear of the vexations or punitive consequences of treble-damage 
suits. Hence, this private antitrust remedy should not be deemed available to reach [Sherman Act] § 2 
monopolies carried on under a nonfraudulently procured patent.”). 
90. Id. at 181. 
91. Id. at 179–80. 
92. See Nobelpharma AB v. Implant Innovations, Inc., 141 F.3d 1059, 1069 (Fed. Cir. 1998) 
(“Consistent with the Supreme Court’s analysis in Walker Process, as well as Justice Harlan’s concurring 
opinion, we have distinguished ‘inequitable conduct’ from Walker Process fraud, noting that inequitable 
conduct is a broader, more inclusive concept than the common law fraud needed to support a Walker 
Process counterclaim . . . . Inequitable conduct in fact is a lesser offense than common law fraud, and 
includes types of conduct less serious than ‘knowing and willful’ fraud.”) (citations omitted). 
93. 15 U.S.C. § 15(a) (1994). 
94. Nobelpharma, 141 F.3d at 1070. 
95. Baxter Intern., Inc. v. McGaw, Inc., 149 F.3d 1321, 1327 (Fed. Cir. 1998); see also Star 
Scientific, Inc. v. R.J. Reynolds Tobacco Co., 537 F.3d 1357, 1367 (Fed. Cir. 2008) (“With respect to 
the materiality prong, we have held that ‘information is material when a reasonable examiner would 
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purposes of showing inequitable conduct “even if it does not meet the standard 
for Rule 56 if, in the totality of the circumstances, a reasonable examiner would 
have considered such information important in deciding whether to allow the 
patent application.”96 In contrast, omitted information was material for Walker 
Process purposes only “if the patent would not have issued ‘but for’ the 
omission.”97  
The Federal Circuit’s en banc decision in Therasense, however, changed the 
legal test for materiality for inequitable conduct purposes. In Therasense, the 
Federal Circuit held “that, as a general matter, the materiality required to establish 
inequitable conduct is but-for materiality.”98 The majority, however, also 
“recognize[d] an exception in cases of affirmative egregious misconduct . . . such 
as the filing of an unmistakably false affidavit.”99 Thus, although the Federal 
Circuit explicitly rejected PTO Rule 56, which defined materiality using a 
“reasonable examiner” standard, the court did not adopt a true but-for test.  
If a unified definition of deceptive intent were adopted, the inequitable 
conduct defense and the Walker Process antitrust cause of action would remain 
separate and distinct legal doctrines, the latter of which being harder to prove. 
First, inequitable conduct has a lower standard for materiality than Walker Process 
fraud. Before Therasense, the Federal Circuit held that inequitable conduct 
“encompass[ed] misconduct less egregious than fraud.”100 Most importantly, 
inequitable conduct included omissions of information that are not relevant to 
 
consider it important in deciding whether to allow the application to issue as a patent.’”) (quoting 
Symantec Corp. v. Computer Assocs. Int’l, Inc., 522 F.3d 1279, 1297 (Fed. Cir. 2008)). 
96. Monsanto Co. v. Bayer Biosci. N.V., 514 F.3d 1229, 1237 n.11 (Fed. Cir. 2008). 
There is a dispute over the precise definition of “materiality” for inequitable conduct purposes: 
Concerning the ‘materiality prong,’ there are two standards for determining whether 
information is material. According to the ‘reasonable examiner standard,’ information is 
material when a reasonable examiner would consider it important in deciding whether to 
allow the application to issue as a patent.” [sic] In 1992, the Patent Office set forth its own 
interpretation of the standard for materiality in Rule 56, which provides that information is 
material if it establishes a prima facie case of unpatentability of a claim or if it refutes or is 
inconsistent with positions taken by the applicant during examination.  
Monica A. De La Paz, Inequitable Conduct: Overview and Current Concepts, 22 NO. 2 INTELL. PROP. & 
TECH. L.J. 12 (2010) (citing Symantec Corp. v. Computer Assocs. Int’l. Inc., 522 F.3d 1279, 1297 
(Fed. Cir. 2008)); see also Monica A. De La Paz, Inequitable Conduct: Overview and Current Concepts, 22 NO. 
2 INTELL. PROP. & TECH. L.J. 12 (Feb. 2010) (citing Digital Control Inc. v. Charles Machine Works, 
437 F.3d 1309, 1316 (Fed. Cir. 2006)) (“In Digital Control Inc. v. Charles Machine Works, a 2006 
decision, the Federal Circuit held that the reasonable examiner standard still applies and is not 
superseded by Rule 56, thus resulting in two separate standards for determining materiality that may 
be applied.”). 
97. United States v. Ciba-Geigy Corp., 508 F.Supp. 1157, 1170 (D. N.J. 1979); see Nobelpharma 
AB v. Implant Innovations, Inc., 141 F.3d 1059, 1070 (Fed. Cir. 1998). 
98. Therasense v. Becton, Dickinson and Co., 649 F.3d 1276, 1291 (Fed. Cir. 2011). 
99. Id. at 1292.; see also id. at 1298 (“The majority defines materiality under a but-for test, with 
an exception for intentionally false affidavits filed with the PTO.”) (O’Malley, J., concurring in part 
and dissenting in part). 
100. Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., 537 F.3d 1357, 1366 (Fed. Cir. 2008). 
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patentability.101 Although Therasense has narrowed the definition of materiality for 
inequitable conduct, that definition remains broader than materiality for Walker 
Process purposes. Walker Process uses true but-for materiality, while Therasense 
adopted what may be termed “but-for plus” since “affirmative egregious 
misconduct” can be material even if the patent would have otherwise issued. As a 
result, even after Therasense, misconduct can be material for inequitable conduct 
purposes but still not give rise to Walker Process liability. 
Second, most instances of inequitable conduct will not give rise to antitrust 
liability because Section 2 of the Sherman Act requires several other elements 
before liability attaches to patent misconduct. For example, the antitrust plaintiff 
must prove that the patentee possesses monopoly power in a relevant market. 
Many Walker Process cases fail because the plaintiff cannot either define a relevant 
market or prove market power therein.102 Another difference between inequitable 
conduct and Walker Process fraud is that only the latter requires the claimant to 
prove reliance. The inequitable conduct defense does not include the element of 
reliance.103 Finally, the Walker Process plaintiff must prove that it has suffered 
antitrust injury and calculate damages.104  
In short, if the Walker Process and inequitable conduct tests both employed 
the same intent element, they would remain separate and distinct legal doctrines.  
D. Deference to Factual Findings 
The Federal Circuit claims to be deferential to jury findings of fact in Walker 
 
101. See Gerald Sobel, Reconsidering the Scope of the Inequitable Conduct Doctrine in View of Supreme 
Court Precedent and Patent Policy, 18 FED. CIRCUIT B. J. 169, 182 (2009) (“Under the Federal Circuit’s 
standard, information is material even when it is neither important nor relevant to patentability.”); 
McMahon & Boyle, supra note 73, at 199 (“Thus, the inequitable conduct defense is not confined to 
instances of misrepresentation that bear on the patentability of claims in an application but may 
involve other types of misrepresentation to the PTO.”); id. at 200 (citing McKesson Info. Solusions, 
Inc. v. Bridge Med., Inc., 487 F.3d 897, 913 (Fed. Cir. 2007)) (“It is well settled that information may 
be material even if that information would not by itself invalidate the claims.”). For example, 
concealing past relationships among declarants and a patent’s assignee may constitute inequitable 
conduct, Ferring B.V. v. Barr Labs., Inc., 437 F.3d 1181, 1231 (Fed. Cir. 2006), but would not provide 
a basis for antitrust liability unless the patent would not have issued had the patent examiner been 
aware of the relationship. Similarly, inappropriate claiming of small-entity status can constitute 
inequitable conduct, Nilssen v. Osram Sylvania, Inc. 504 F.3d 1223 (Fed. Cir. 2007), but would not 
constitute Walker Process fraud. 
102. HOVENKAMP, JANIS, LEMLEY & LESLIE, supra note 17, at 11–49. 
103. C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1365 (Fed. Cir. 1998) (“The requirements 
of common law fraud are in contrast with the broader sweep of ‘inequitable conduct,’ an equitable 
defense that may be satisfied when material information is withheld with the intent to deceive the 
examiner, whether or not the examiner is shown to have relied thereon.”); see also Unitherm Food 
Sys., Inc. v. Swift-Eckrich, Inc., 375 F.3d 1341, 1361 (Fed. Cir. 2004) (“The best evidence of the 
fourth element of the alleged fraud, the PTO’s justifiable reliance on Singh’s deception that induced 
PTO action, is that the PTO issued the patent.”). 
104. See Unitherm Food Sys., Inc. v. Swift-Eckrich, Inc., 375 F.3d 1341, 1355 (Fed. Cir. 2004). 
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Process cases.105 For example, it claims that “[t]he jury was entitled to find all of 
[one side’s] evidence credible and to disbelieve every assertion that [the other side] 
made about a disputed fact.”106 The Federal Circuit has opined that “[t]he drawing 
of inferences, particularly in respect of an intent-implicating question . . . is 
peculiarly within the province of the fact finder that observed the witnesses.”107 
But there is reason to believe that Federal Circuit judges do not defer as they 
should.  
In 2008, the Federal Circuit announced an evidentiary standard for drawing 
inferences that comes close to eliminating altogether deference to trial judges’ 
findings regarding inequitable conduct. In Scanner Technologies Corp. v. Icos Vision 
Systems Corp., the court held that “[w]henever evidence proffered to show either 
materiality or intent is susceptible of multiple reasonable inferences, a district 
court clearly errs in overlooking one inference in favor of another equally 
reasonable inference.”108 The en banc Therasense court embraced this approach.109 
On its face, this standard is nonsensical because it implies that when there are two 
“equally reasonable inference[s],” the trial court errs by picking either one. More 
importantly, under this standard, the Federal Circuit has essentially usurped the 
trial judge’s fact-finding role entirely. For example, employing this standard, the 
Federal Circuit reversed the trial judge’s finding of inequitable conduct in a case 
because the appellate judges concluded that “deceptive intent is not ‘the single 
most reasonable inference able to be drawn from the evidence.’”110 If it is clear 
error to not use the “single most reasonable inference” and the Federal Circuit 
decides the single most reasonable inference, then there is no deference on fact-
finding at all. 
Even before the announcement of this new nondeferential standard, patent 
 
105. Id. at 1361 (referring to “the limited factual review that we apply to sufficiency of 
evidence arguments about jury findings”). 
106. Id. 
107. Molins PLC v. Textron, 48 F.3d 1172, 1180–81 (Fed. Cir. 1995). When reviewing an 
infringement defendant’s successful use of an inequitable conduct defense, the Federal Circuit claims 
to “review the underlying factual determinations for clear error, but we review the ultimate decision as 
to inequitable conduct for an abuse of discretion.” Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., 
537 F.3d 1357, 1365 (Fed. Cir. 2008) (citing Cargill, Inc. v. Canbra Foods, Ltd., 476 F.3d 1359, 1364–
65 (Fed. Cir. 2007)); Aventis Pharma S.A. v. Amphastar Pharm.,, Inc., 525 F.3d 1334, 1343 (Fed. Cir. 
2008) (“We review a district court’s finding of intent to deceive for clear error.”); Monsanto Co. v. 
Bayer Bioscience N.V., 514 F.3d 1229, 1233 (Fed. Cir. 2008); Cargill, Inc. v. Canbra Foods, Ltd., 476 
F.3d 1359, 1364 (Fed. Cir. 2007). A finding of intent will not be overturned “in the absence of a 
‘definite and firm conviction’ that a mistake has been made.” Hoffmann-LaRoche, Inc. v. Promega 
Corp., 323 F.3d 1354, 1359 (Fed. Cir. 2003) (quoting Molins PLC v. Textron, Inc., 48 F.3d 1172, 1178 
(Fed. Cir. 1995)). Thus, when “the district court’s determination of inequitable conduct is based on a 
clearly erroneous finding of materiality and/or intent, it constitutes an abuse of discretion and must 
be reversed.” Star Scientific, 537 F.3d at 1365 (Fed. Cir. 2008) (citing Impax Labs., Inc. v. Aventis 
Pharm., Inc., 468 F.3d 1366, 1375 (Fed. Cir. 2006)). 
108. 528 F.3d 1365, 1376 (Fed. Cir. 2008). 
109.  Therasense v. Becton, Dickinson and Co., 649 F.3d 1276, 1291 (Fed. Cir. 2011). 
110. Ariad Pharm., Inc. v. Eli Lilly & Co., 560 F.3d 1366, 1379 (Fed. Cir. 2009). 
Assembled Issue 2 11-7-11 (Do Not Delete) 11/7/2011 10:16 AM 
346 UC IRVINE LAW REVIEW [Vol. 1:2 
 
scholars have observed that the Federal Circuit often does not defer to the factual 
findings of juries. The appropriate level of appellate deference is a function of 
whether the appellate court is reviewing a finding of fact or a holding of law, the 
former receiving a much higher degree of deference.111 Much evidence suggests 
that the Federal Circuit often essentially applies de novo review to questions of 
fact. Professor Arti Rai has argued that “[i]gnoring conventional allocation-of-
power principles that give trial courts primary authority over factual questions, the 
Federal Circuit has asserted power over fact.”112 For example, the Federal Circuit 
often reviews infringement determinations de novo113 and “in important cases 
involving the enablement requirement, the court has paid mere lip service to 
principles of deferential review.”114 Professor Rai explains:  
The court has been quite aggressive in its application of de novo review. 
Two recent empirical studies estimate that the Federal Circuit has 
disagreed with lower court claim construction in at least one-third of all 
appealed cases. Notably, the Federal Circuit’s plenary review of claim 
construction can have something of a domino effect, leading the court to 
arrogate power over issues even it admits are factual, such as 
infringement. This domino effect works as follows: because claim 
construction bears heavily on the question of infringement, a decision to 
overturn the district court’s claim construction often means that a new 
determination regarding infringement must be made. At that point, the 
Federal Circuit faces two choices. It can either remand to the district 
court for cumbersome new fact-finding on the question of infringement, 
or it can simply determine the question of infringement itself. Even 
though infringement is, under the Federal Circuit’s own jurisprudence, a 
factual issue, the Federal Circuit is often reluctant to remand for a new 
trial on infringement. Rather, the court simply declares that there is no 
factual dispute with respect to infringement. As a consequence, de novo 
review of claim construction effectively becomes de novo review of 
infringement.115  
 
111. See Jeanne C. Fromer, Patentography, 85 N.Y.U. L. Rev. 1444, 1460 (2010) (“The degree of 
deference accorded to district court determinations in patent law depends on whether they are labeled 
as factual or legal issues. The Supreme Court has ruled that the Federal Circuit, like the other federal 
courts of appeal, must review factual findings deferentially for clear error.”) (citing Dennison Mfg. 
Co. v. Panduit Corp., 475 U.S. 809, 809–11 (1986) (per curiam)). 
112. Arti K. Rai, Specialized Trial Courts: Concentrating Expertise on Fact, 17 BERKELEY TECH. L.J. 
877, 883 (2002). 
113. See William C. Rooklidge and Matthew Weil, Judicial Hyperactivity: The Federal Circuit’s 
Discomfort With Its Appellate Role, 15 BERKELEY TECH. L.J. 725 (2000). 
114. Rai, supra note 112, at 886; see Timothy R. Holbrook, Patents, Presumptions, and Public 
Notice, 86 IND. L.J. 779 (2011). 
115. Rai, supra note 112, at 884–85 (citing Christian Chu, Empirical Analysis of the Federal 
Circuit’s Claim Construction Trends, 16 BERKELEY TECH. L.J. 1075, 1104 (2001)) (giving figure of 44%); 
Kimberly A. Moore, Are District Court Judges Equipped to Resolve Patent Cases?, 15 HARV. J.L. & TECH. 1, 
11 (2001) (giving figure of 33%). 
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Whether this overreaching is the result of an honest mistake or a naked 
power grab,116 the result for litigants is the same: factual findings at the district 
court level carry little weight on appeal before the Federal Circuit.  
These observations by patent scholars also resonate in cases involving 
allegations of deceptive conduct by patent applicants. The Federal Circuit seems 
prone to overturning jury verdicts for antitrust plaintiffs in Walker Process lawsuits 
as well as findings of inequitable conduct in patent infringement cases.117 In 
Walker Process cases, the issue of whether a patent applicant intended to deceive 
the PTO is a factual question and thus the determination by the jury—or the 
district judge in a bench trial—is entitled to substantial deference. Nevertheless, 
the Federal Circuit appears unwilling to defer to jury findings in Walker Process 
cases involving fraud by omission. For example, in Dippin’ Dots, the Federal 
Circuit reversed the jury’s finding of fraud because “an omission . . . could happen 
for any number of nonfraudulent reasons—the applicant could have had a good-
faith belief that disclosure was not necessary, or simply have forgotten to make the 
required disclosure.”118 But the jury clearly rejected those alternative 
interpretations when it found—as a matter of fact—that the patent applicant 
intended to deceive the PTO. The Federal Circuit, essentially, did not treat the 
jury’s verdict as based on a factual finding entitled to deference and instead the 
Federal Circuit simply substituted its own interpretation of the patent applicant’s 
decision to withhold material information.  
The Federal Circuit should defer more to factual findings of fraudulent 
intent for two reasons. First, it is reasonable for a jury to infer deceptive intent 
from an omission when the applicant knows about a particular fact, knows that it 
has a duty to disclose that fact, and conceals that fact from the patent examiner. In 
Dippin’ Dots, the Federal Circuit claimed to defer to the jury by stating that the 
“jury was of course allowed to disbelieve or discount evidence tending to support 
this claim,”119 but then went on to reject the jury’s finding of deceptive intent 
because “the defendants submitted no evidence of their own—aside from the 
absence of the Festival Market sales from the prosecution record—which 
affirmatively shows DDI’s fraudulent intent.”120 But the court gave no guidance as 
to what this “affirmative” evidence would look like—especially given the fact that 
 
116. See Fromer, supra note 111, at 1475 (“Some critics wonder whether the Federal Circuit’s 
labeling of some questions as legal—while thoroughly reviewing other, ostensibly factual questions—
might be a ‘power grab.’”) (citing Peter Zura, Looking for Fire Amidst the Smoke—Is the Federal Circuit 
Really Exceeding Its Appellate Authority in Patent Infringement Cases?, 12 U. BALT. INTELL. PROP. L.J. 1, 22 
(2003)). 
117. See, e.g., C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1368 (Fed. Cir. 1998) (reversing 
jury verdict for Walker Process plaintiff); Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., 537 F.3d 
1357, 1367–68 (Fed. Cir. 2008) (reversing finding of inequitable conduct). 
118. Dippin’ Dots v. Mosey, 476 F.3d 1337, 1347 (Fed. Cir. 2007). 
119. Id. at 1348. 
120. Id.  
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no patent applicant memorializes his fraudulent intent in writing and, under 
longstanding precedent, such intent must be inferred. The Federal Circuit opined 
that “intent cannot be shown merely from the absence of evidence which would 
come about from the jury’s discounting DDI’s explanation.”121 But when the 
patent applicant knows about the sales and claims that it did not disclose them 
because it thought it did not have to, and the jury finds that the applicant lied in 
order to conceal material information, the jury’s factual finding that the applicant 
is lying supports a finding of deceptive intent. In contrasting omissions with 
misstatements made during the prosecution of the patent, the Dippin’ Dots court 
asserted that “to find a prosecution omission fraudulent there must be evidence of 
intent separable from the simple fact of the omission. A false or clearly misleading 
prosecution statement may permit an inference that the statement was made with 
deceptive intent.”122 The Federal Circuit apparently ignored the fact that the jury 
did find that the patentee made an affirmative misrepresentation: it happened at 
trial. The patentee claimed that it withheld the information for a legitimate reason 
and the jury concluded that that statement was false. That factual conclusion 
deserves deference.123  
Second, the Federal Circuit should also defer to factual findings of deceptive 
intent because the fact finder is better positioned to make such a determination. In 
reviewing findings of deceptive intent, the Federal Circuit gives lip service to the 
principle that “credibility determinations are an aspect of fact-finding that 
appellate courts should rarely reverse.”124 Such pronouncements, however, appear 
insincere given the court’s proclivity to reverse these precise factual findings, as 
the court did in Dippin’ Dots. While it may be possible to construct an argument 
that “in patent law, when the Federal Circuit’s judges are greater patent experts 
than the district court’s, the Federal Circuit might seem to be in a better position 
to review technological facts and credibility,”125 patent expertise is less relevant 
when determining credibility regarding deceptive intent. More importantly, not 
being present at trial, the Federal Circuit judges have little basis for evaluating 
witness credibility, including demeanor, speech patterns and body language—all of 
the various factors that jurors assess when determining whether a witness is telling 
the truth or being deceptive.126  
 
121. Id.; see also Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., 537 F.3d 1357, 1367–68 
(Fed. Cir. 2008) (reversing district count finding of deceptive intent regarding inequitable conduct). 
122. Dippin’ Dots, 476 F.3d at 1347. 
123. See Star Scientific, 537 F.3d at 1367–68 (“The district court indicated that it viewed [the 
patentee’s] testimony as not credible and that this credibility determination was a major basis for its 
finding of deceptive intent.”). The Federal Circuit reversed the fact finder. Id.  
124. Id. 
125. Fromer, supra note 111, at 1475. 
126. See id. at 1476 (“[T]he Federal Circuit’s usurpation of factfinding is not ideal. For one 
thing, the Federal Circuit typically sees only a cold record, usually as abridged by the litigants’ lawyers. 
It neither evaluates witness testimony in the first instance, nor sees all of the evidence—testimonial 
and documentary—that comes before the district court . . . .”). 
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E. An Antitrust Remedy for Failing to Disclose Material Sales Activity 
If a patent applicant conceals material sales activity, there should be negative 
consequences for the failure to disclose. The patent law response is the defense of 
inequitable conduct, which renders the claims in the patent application 
unenforceable if the infringement defendant can establish the elements of the 
defense.127 The antitrust response is the Walker Process cause of action for illegal 
monopolization. 
Antitrust liability is the proper response when a patent applicant knows that 
she has a duty to disclose, fails that duty, and uses the fraudulent patent to acquire 
or maintain a monopoly. Fraudulently procured patents can wreak havoc on a 
competitive economy.128 Although the patent system is the most immediate victim 
of patent fraud through omission, patent law provides an inadequate response to 
such misconduct.  
Patent law’s reliance on the inequitable conduct defense to penalize omission 
of material information is insufficient for several reasons. First, to be effective, the 
legal response to the patent misconduct that distorts markets and reduces 
innovation must accomplish several related goals: (1) prevent owners of tainted 
patents from exercising the exclusionary rights associated with the patent; (2) 
disgorge the ill-gotten gains associated with the misconduct; (3) deter future 
misconduct; and (4) compensate the victims of the misconduct.129 While the 
inequitable conduct defense can achieve the first step and perhaps some modicum 
of deterrence, the patent system is not designed to disgorge or compensate.130 As 
a result, if the only response to patent fraud is the inequitable conduct defense, 
patent fraud would be profitable for patentees. Ill-gotten gains are not disgorged 
and the victims of the patent fraud are not entitled to any compensation under 
patent law. So, under patent law, the transgressor is entitled to keep any supra-
competitive profits received before the inequitable conduct defense invalidates the 
patent.  
Second, by the time that a patent is rendered unenforceable through the 
inequitable conduct defense, the misconduct may already be net profitable. Absent 
their inequitable conduct, the applicant would probably not receive the patent.131 
 
127. See supra notes 26–38 and accompanying text. 
128. See supra notes 3–7 and accompanying text. 
129. Leslie, supra note 88, at 1286. 
130. Id. In theory, deterrence could be achieved at the attorney level. The individual patent 
attorney may also be punished, Cotropia, supra note 25, at 763, but this rarely happens. Furthermore, 
attorney sanctions do not deter all misconduct because some attorneys will try to be willfully ignorant 
of invalidating sales. See Brasseler v. Stryker Sales Corp., 93 F.Supp.2d 1255, 1264 (S.D.Ga. 1999) 
(“But patent counsel’s studied refusal to timely investigate and disclose after the fact easily supplies 
the inequitable conduct needed to satisfy 35 U.S.C. § 285.”). Also patentees may try to “‘empty-head’ 
their own patent counsel” by denying them material information about invalidating sales. Id. at 1264. 
131. Brown, supra note 63, at 612–13 (“[I]f the patentee committed inequitable conduct, then 
the patent is probably invalid.”); Id. at 614 (“[P]atentees that commit inequitable conduct typically 
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A patent owner with an invalid patent—even one that others suspect to be 
invalid—can expect to earn more profits than a comparable firm without the 
patent.132 If the patent is later rendered unenforceable pursuant to the inequitable 
conduct doctrine, the deceptive patent applicant has already collected licensing 
fees, charged a supracompetitive price, and earned a supracompetitive profits. In 
some cases, by the time that the court invalidates the patent, the patent may have 
already expired. For example, in Walker Process itself, the patentholder brought the 
infringement suit when there were only six months left before the patent expired. 
By the time that the court ruled on either an inequitable conduct defense or an 
antitrust counterclaim, the claimed invention would have already entered the 
public domain.133 Under these facts, the inequitable conduct defense has no teeth. 
A legal doctrine that makes an expired patent unenforceable is worthless. 
In contrast to patent law, an antitrust response to patent fraud achieved 
through the omission of material sales activity with an intent to deceive the PTO 
can achieve all of the necessary goals. First, the patent is rendered unenforceable 
as it would be under the inequitable conduct defense.134 The holder of the 
fraudulent patent can no longer wield it as a club to threaten competitors and to 
exclude them from the market. 
Further, because the enforcement of fraudulently procured patents is 
monopoly conduct, if the other elements of a Section 2 claim are present, the 
antitrust plaintiff is entitled to treble damages. This would be triple the lost profits 
of illegally excluded competitors. In those jurisdictions that allow consumers 
standing to pursue Walker Process lawsuits, consumers would be entitled to triple 
the overcharge that they paid because of the fraudulent patent. Antitrust’s treble 
damages should both disgorge the patentee’s ill-gotten gains and compensate 
victims who suffered damages caused by the fraudulent patent. As a result, 
antitrust liability for fraudulent omissions of sales activity better achieves the goals 
of the patent system.  
In short, antitrust liability for omissions of patent-invalidating sales 
information—done with deceptive intent—better protects the patent system from 
fraud by omission of sales activity. So long as the Federal Circuit’s antitrust 
jurisprudence interprets deceptive intent in a manner that makes it unreasonably 
difficult for plaintiffs to establish Walker Process liability, the patent system is 
unlikely to deter fraud by omission. The net effect of liberalizing the means of 
proving deceptive intent for antitrust purposes is to render patent fraud not cost-
 
have patents that are invalid when the court decides both issues.”). 
132. Leslie, supra note 3. 
133. See Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 152 (1989) (“[A]fter 
the expiration of a federal patent, the subject matter of the patent passes to the free use of the public 
as a matter of federal law.”). 
134. In those cases in which the Walker Process cause of action is brought as a counterclaim, 
the infringement defendant would likely raise an inequitable conduct defense and thus the patent may 
be rendered unenforceable before the antitrust claim is even considered. 
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beneficial and thus to deter future fraud. 
IV. POSSIBLE CONCERNS 
Changing patent law to make it easier to impose antitrust liability on 
patentees who withhold material sales information from patent examiners will be 
controversial. To some, it may smack of strict liability. Others may fear that the 
antitrust cause of action may become indistinguishable from the inequitable 
conduct defense. Finally, the concern that patent applicants will inefficiently 
overcomply with the new requirements will dissuade some readers from 
embracing this Article’s proposal. This section addresses these concerns.135 
A. Strict Liability 
Under the proposal in Part III, deceptive intent can be shown through 
circumstantial evidence of a patentee’s knowing omission of certain sales 
information. This is not a revolutionary change given that intent has always been 
provable through circumstantial evidence.136 Some may fear that the suggestions 
in Part III are tantamount to strict liability because materiality can provide 
evidence of intent. Strict conflation would be misguided because “[w]ith regard to 
the deceptive intent prong, [the Federal Circuit has] emphasized that ‘materiality 
does not presume intent, which is a separate and essential component of 
inequitable conduct.’”137  
The proposals do not constitute strict liability, however, because the patentee 
who is an antitrust defendant can escape liability by showing that she lacked the 
requisite intent. First, the patentee can argue that she made an honest judgment 
call that happened to be wrong. Good faith negates deceptive intent138 and 
represents a defense against fraud, including Walker Process fraud.139 It may be 
harder to convince juries of good faith when the disclosure requirements are more 
 
135. Another potential objection is that infringement defendants may file weak Walker Process 
claims that they otherwise would not. A uniform standard for deceptive intent for inequitable conduct 
and antitrust fraud purposes should not have a meaningful effect on the course of infringement 
litigation. First, Walker Process counterclaims are already ubiquitous. Second, any infringement 
defendant induced to bring a Walker Process claim because of the lower intent requirement would 
already be making an inequitable conduct defense, which under the proposal has the same intent 
requirement. Consequently, the discovery sought by the infringement defendant should remain the 
same. Third, weak Walker Process claims will fail because the Walker Process plaintiff must still prove 
that the patent applicant made a material omission or misrepresentation that caused a patent to issue 
that should not have. 
136. Cotropia, supra note 25, at 734 (“Circumstantial evidence can be used to prove the 
relevant party’s intent.”). 
137. Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., 537 F.3d 1357, 1366 (Fed. Cir. 2008) 
(quoting GFI, Inc. v. Franklin Corp., 265 F.3d 1268, 1274 (Fed. Cir. 2001)). 
138. Kingsdown Med. Consultants, Ltd. v. Hollister, Inc., 863 F.2d 867, 872 (Fed. Cir. 1988) 
(en banc). 
139. See C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1365 (Fed. Cir. 1998) (“Good faith is 
an absolute defense to the charge of common law fraud.”). 
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clear and more rigorous.140 However, if the patentee can provide “a credible 
reason for the withholding, the materiality of the references standing alone is not 
sufficient to establish intent.”141 The failure to have a good faith explanation can 
be evidence of deceptive intent.142  
Second, the patentee can argue that the omission was the result of a 
transcription error, not a conscious decision or intentional act. The Federal Circuit 
has suggested that a “failure to disclose . . . due purely to inadvertence” is 
insufficient to establish deceptive intent.143 If the patentee can convince the fact 
finder that she made a clerical mistake—not a deliberate omission—then this 
would negate deceptive intent. This, however, is a question of fact for the jury (or 
trial judge in a bench trial) to determine based on witness credibility.  
In sum, direct evidence of intent to defraud the Patent Office almost never 
exists. This Article argues that a patentee’s omission of particular categories of 
sales data is prima facie evidence of deceptive intent. There is no strict liability 
because the jury must find intent and the patentee can refute the evidence of 
intent. Although the patentee can argue that the omission was a good faith 
judgment call or a transcription error, the jury is free to disbelieve the patentee’s 
explanation of the omission and to infer intent from the omission. Appellate 
courts should not interfere with the province of the jury on what is an inherently 
factual issue. Ultimately, this is a jury question and appellate courts should respect 
its decision. 
B. Too Costly 
Some may argue that any change in the method of proving deceptive intent 
that encourages greater disclosures could increase the cost of every patent 
application. This arguably would be inefficient because only a minority of patents 
are actually enforced. Mark A. Lemley has argued that resources are better spent 
evaluating those patents that prove to be valuable instead of laboriously vetting 
every patent application, most of which will not affect market competition.144 The 
point is well taken that neither patent applicants nor patent examiners should 
overinvest in the search for prior art during the patent examination process. But 
 
140. Purdue Pharma L.P. v. Endo Pharm., Inc., 438 F.3d 1123, 1133–35 (Fed. Cir. 2006) (“[A] 
patentee facing a high level of materiality and clear proof that it knew or should have known of that 
materiality, can expect to find it difficult to establish ‘subjective good faith’ sufficient to prevent the 
drawing of an inference of intent to mislead.”). 
141. Pfizer, Inc. v. Teva Pharm. USA, Inc., 518 F.3d 1353, 1367 (Fed. Cir. 2008). 
142. See Praxair, Inc. v. ATMI, Inc., 543 F.3d 1306, 1315 (Fed. Cir. 2008).  
The Therasense majority held that “[t]he absence of a good faith explanation for withholding a material 
reference does not, by itself, prove intent to deceive.” Therasense v. Becton, Dickinson and Co., 649 
F.3d 1276, 1291 (Fed. Cir. 2011) (emphasis added). This suggests that the lack of an explanation can 
help build a circumstantial case, even if it is not dispositive. 
143. Aventis Pharma S.A. v. Amphastar Pharm., Inc., 176 F. App’x 117, 123 (Fed. Cir. 2006). 
144. Mark A. Lemley, Rational Ignorance at the Patent Office, 95 NW. U. L. REV. 1495 (2001). 
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these arguments are not particularly persuasive in the context of sales information. 
More rigorous disclosure requirements regarding the patentees’ own sales 
activity is reasonable. It is important not to impose unreasonable burdens on 
patent applicants. For example, the patent applicant bears no affirmative duty to 
search for prior art.145 The patent applicant does not have to research prior art 
because that would impose too great a burden, especially on independent 
inventors. But the patent applicant already knows about its sales activity. Requiring 
the applicant to disclose the information to the PTO does not represent an 
onerous burden because patent applicants know about their own sales activity. 
From an efficiency standpoint, they should bear the burden of producing all 
potentially relevant information because they are the lowest-cost provider of that 
information.146 As Polk Wagner has explained, “[a]mong the ‘parties’ to the patent 
transaction, the patentee is either the best informed or the one who can most 
easily and cheaply become the best informed about the context of her 
innovation.”147 This is particularly true in the context of the patentee’s own sales 
history.148 
C. Overcompliance 
Another concern may be that increasing the potential liability for omissions 
by making it easier to infer deceptive intent may lead patent applicants to 
overcomply by providing too much information, including much that is 
 
145. FMC Corp. v. Hennessy Indus., Inc., 836 F.2d 521, 526 n.6 (Fed. Cir. 1987) (“As a 
general rule, there is no duty to conduct a prior art search, and thus there is no duty to disclose art of 
which an applicant could have been aware.”). 
146. See Cotropia, supra note 25, at 781. 
147. R. Polk Wagner, Reconsidering Estoppel: Patent Administration and the Failure of Festo, 151 U. 
PA. L. REV. 159, 213 (2002); Cotropia, supra note 25, at 754 (“The doctrine generates valuable 
information by placing information production responsibilities on a low-cost provider. Production of 
information costs the applicant, but the doctrine limits this cost by requiring the applicant to consider 
only the information already in her possession.”). 
148. The on-sale bar applies not only to sales and offers by the patent applicant, but by any 
third party whether or not it has a relationship with the patent applicant. Special Devices, Inc. v. 
OEA, Inc., 270 F.3d 1353, 1355 (Fed. Cir. 2001) (“By phrasing statutory bar in the passive voice, 
Congress indicated that it does not matter who places the invention ‘on sale’; it only matters that 
someone—inventor, supplier or other third party—placed it on sale.”); J.A. LaPorte, Inc. v. Norfolk 
Dredging Co., 787 F.2d 1577 (Fed. Cir. 1986) (The “on sale” bar “is not limited to sales by the 
inventor or one under his control, but may result from activities of a third party.”); see Evans Cooling 
Sys., Inc. v. General Motors Corp., 125 F.3d 1448 (Fed. Cir. 1997) (on-sale bar triggered by sales of 
third party that misappropriated applicant’s invention); see also 2 DONALD S. CHISUM, CHISUM ON 
PATENTS, § 6.02 [6] (2008) (“[T]he public use and on sale bars apply even when the activity is by a 
person or persons who independently create the invention.”). 
 Third-party sales are different because the patent applicant did not make them and may not 
have direct information about them. If the reason for inferring fraud from the withholding of the 
material information in the sales context is that the patent holder has unique information, this premise 
is not applicable when the sales were made by a third party. Nevertheless, if the patent applicant had 
actual knowledge of those third-party sales and still declined to disclose them, that could still provide 
the basis for an inequitable conduct offense or a Walker Process counterclaim. 
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extraneous, to patent examiners.149 Scholars have argued that the urge to 
overdisclose exists currently because a finding of inequitable conduct invalidates 
the entire patent.150 Risk-averse patent applicants may overcomply to avoid the 
possibility of being found to have engaged in inequitable conduct by withholding 
information.151 Less valid reasons to overproduce material for patent examiners 
include the desire to bury bad information in a flood of irrelevant records152 and 
the desire of an unscrupulous attorney to run up the legal bills.153 
The costs of overcompliance can be great. As patent applicants overload the 
examiner with irrelevant information, the examiner may overlook facts that would 
result in denial of the patent.154 The pressure to overcomply may increase the 
price of patent prosecution.155 The submission of irrelevant prior art reference 
waste resources.156 The ultimate effect of overcompliance may be to reduce patent 
quality.157 
The arguments about overcompliance are well taken. The problem, however, 
 
149. Therasense v. Becton, Dickinson and Co., 649 F.3d 1276, 1289 (Fed. Cir. 2011) (“With 
inequitable conduct casting the shadow of a hangman’s noose, it is unsurprising that patent 
prosecutors regularly bury PTO examiners with a deluge of prior art references, most of which have 
marginal value.”). 
150. Cotropia, supra note 25, at 729 (“[T]he doctrine, through the extreme legal and extra-legal 
costs it currently imposes, incentivizes inventors and, in particular, patent attorneys to overcomply by 
submitting all information, regardless of relevance, to the USPTO.”). 
151. Id. at 768 (“Even if the information is not material to the claimed invention, disclosure 
absolves any potential violation of the doctrine.”). 
152. Brown, supra note 63, at 619 (“Many patent applicants submit massive amounts of prior 
art references in Information Disclosure Statements (‘IDS’) to avoid any later inequitable conduct 
allegations that they omitted any material information, but in so doing bury relevant references among 
those having little or no significance.”); cf. Molins PLC v. Textron, Inc., 48 F.3d 1172, 1184 (Fed. Cir. 
1995) (“‘[B]urying’ a particularly material reference in a prior art statement containing a multiplicity of 
other references can be probative of bad faith.”). 
153. Cotropia, supra note 25, at 769 (“Added to this is the fact that overcompliance generates 
more legal fees. The attorney gets to charge her client for the time required to submit the additional 
information and continue prosecution if necessary.”). 
154. See id. at 771 (“Information overload can even cause the examiner to become so 
overwhelmed that she does not even attempt to sift through the applicant’s submissions. She ignores 
them completely.”); Therasense, 649 F.3d at 1289  (“This tidal wave of disclosure makes identifying the 
most relevant prior art more difficult.”). 
155. Cotropia, supra note 25, at 772. 
156. See id. at 777 (“Reading and evaluating a reference is the most attorney intensive, and 
thus expensive, part of submitting information to the USPTO.”). 
157. See id. at 729 (“The tremendous incentive for applicants to overcomply can actually 
decrease patent quality.”). Professor Cotropia explains: 
Overcompliance puts any improvement in patent quality created by the inequitable 
conduct doctrine at risk. It overloads the examiner with information that, in most 
instances, is immaterial. The examiner, with an extremely small amount of time to examine 
highly technical subject matter, does not process all of the submitted information or 
ignores it altogether, erasing any quality gains. In fact, the doctrine may end up doing more 
harm than good. Overcompliance can so stress the examiner as to impair her ability to 
make a sound decision based on the information she does process. Overcompliance 
further prices inventors out of the patent system, causing its own set of societal harms.  
Id. at 770. 
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is less applicable to sales activity than other prior art references. The submission 
of excessive and unnecessary references is primarily a concern in the context of 
prior art references that are potentially limitless as when a patent applicant floods 
the Patent Office with tangential studies and irrelevant reports in foreign 
languages.158 In contrast, sales activity is more finite and patent applicants are less 
able to deluge patent examiners with irrelevant sales information. Also, as 
Professor Chris Cotropia notes, “The chances of overload are particularly high 
when the information is highly technical or complex.”159 
Compared to other aspects of the patent examination process, sales 
information is not likely to be either technical or complex. 
Still, any enhancement of disclosure rules should be implemented in a 
manner that reduces the risk of inefficient overcompliance. Rules should 
encourage disclosure, but that disclosure should be in a form that allows for 
efficient processing. For example, the Patent Office could reduce the risk of 
information overload by requiring an itemized list of all sales activity. This reduces 
the risk of suspect sales being buried in documents and a patent examiner not 
reviewing them. Further, patent applicants could be required to include relevancy 
statements with their sales activity disclosure.160 This would reduce the risk of 
extraneous disclosures designed to overburden the examiner. 
In any case, the problem of overcompliance with Patent Office disclosure 
requirements must be balanced against the risk of undercompliance. While some 
patent applicants may overcomply by producing irrelevant references, others are 
undercomplying by withholding material information, as the Dippin’ Dots case 
illustrates. The costs of undercompliance are significant as well. The omission is 
dangerous because the information is not in the PTO record. In the event of 
overcompliance, at least the relevant information is in the patent application for 
later infringement defendants to easily discover. When a patent issues that should 
not have because the examiner did not receive patent-invalidating information, the 
patentee improperly acquires the ability to exclude competitors from the market 
and patentees may be able to secure tens of millions of dollars in monopoly 
profits.161 Because the potential gains from deception by omitting patent-
invalidating sales information are so great, the consequences of deception must be 
 
158. Cf. John R. Thomas, Collusion and Collective Action in the Patent System: A Proposal for Patent 
Bounties, 2001 U. ILL. L. REV. 305, 315 (2001) (“Where the applicant is already well informed of the 
prior art, the specter of inequitable conduct too often causes applicants to submit virtually every 
reference of which they are aware.”). 
159. Cotropia, supra note 25, at 771. 
160. Id. at 743 (“Relevancy statements help the USPTO understand the submitted 
information in the context of patent application. The USPTO does not need to spend as much time 
digesting the submitted information. Nor does the USPTO have to expend as much energy placing 
the submitted information in the context of the patentability of the claimed invention. Such 
statements facilitate a better and more efficient examination.”). 
161. Leslie, supra note 3, at 124. 
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correspondingly great. Antitrust liability imposes a more meaningful cost on 
patent fraud and therefore is more likely to deter deceptive omissions of 
information that would cause a patent examiner to reject an application based on 
the on-sale bar. 
V. CONCLUSION 
Because antitrust liability is seen as a harsh weapon, the Federal Circuit is too 
quick to find an absence of deceptive intent. This invites fraud by making fraud by 
omission appear profitable. Courts should not require antitrust plaintiffs to 
provide more evidence of deceptive intent for Walker Process purposes than 
infringement defendants need to provide in order to prevail on an inequitable 
conduct defense. If courts did this, it should enhance deterrence of patent fraud. 
 
 
 
 
